In addition, the DPP-4 inhibitor selegiline has been shown to alleviate DKD by inhibiting TGF-β1/Smad signaling and upregulating heme oxygenase-1 (HO-1) expression in MCs 190, 191. This evidence concerns the gene TGFB1 and diabetic kidney disease.